|Bid||2.2700 x 900|
|Ask||2.3400 x 3200|
|Day's range||2.2500 - 2.4100|
|52-week range||2.2200 - 5.1900|
|Beta (5Y monthly)||2.15|
|PE ratio (TTM)||N/A|
|Earnings date||29 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.00|
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the...
Good morning, and thank you for joining the GlycoMimetics call. Brian will follow Rachel to provide an overview of the company's financial position, and we'll then open the call for Q&A. Our Chief Scientific Officer, Dr. John Magnani; and our Chief Medical Officer, Dr. Eric Feldman will join us in the Q&A to address your questions.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events. Cash and cash equivalents at March 31, 2021 were $132.5 million.